cetylpyridinium chloride anhydrous has been researched along with pioglitazone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al Majali, K; Betteridge, DJ; Cooper, MB; Luc, G; Staels, B; Taskinen, MR | 1 |
| Beltran, A; Bladé, C; Correig, X; Díaz, M; Ibañez, L; Mallol, R; Rodriguez, MA; Samino, S; Vinaixa, M; Yanes, O | 1 |
2 trial(s) available for cetylpyridinium chloride anhydrous and pioglitazone
| Article | Year |
|---|---|
The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diet; Diterpenes; Fatty Acids, Nonesterified; Female; Health; Humans; Insulin; Lipid Metabolism; Lipoprotein Lipase; Lipoproteins; Liver; Male; Middle Aged; Pioglitazone; Retinyl Esters; Thiazolidinediones; Triglycerides; Vitamin A | 2006 |
Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.
Topics: Abdominal Fat; Biomarkers; Carotid Intima-Media Thickness; Chromatography, Gas; Chromatography, Liquid; Dicarboxylic Acids; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Flutamide; Health; Humans; Linoleic Acid; Lipoproteins; Magnetic Resonance Spectroscopy; Metabolomics; Metformin; Multivariate Analysis; Oxidation-Reduction; Pioglitazone; Polycystic Ovary Syndrome; Spectrometry, Mass, Electrospray Ionization; Thiazolidinediones; Young Adult | 2011 |